Antibody-drug Conjugates for Breast Cancer Treatment

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Antibody-drug conjugates (ADCs) represent a significant advancement in targeted cancer therapy.
• ADCs are engineered to selectively deliver potent cytotoxic agents to malignant cells, minimizing systemic toxicity.

Purpose of the Study:

• To provide a comprehensive overview of antibody-drug conjugates (ADCs) in cancer treatment.
• To discuss the mechanisms of action, clinical applications, and toxicological profiles of approved ADCs for breast cancer.

Main Methods:

• Review of scientific literature on antibody-drug conjugates.
• Analysis of approved ADCs for breast cancer, including ado-trastuzumab emtansine, fam-trastuzumab deruxtecan-nxki, and sacituzumab govitecan.

Main Results:

• Discussion of the specific components of ADCs: monoclonal antibody, cytotoxic drug, and linker.
• Detailed examination of the therapeutic strategies and outcomes associated with key breast cancer ADCs.

Conclusions:

• Antibody-drug conjugates are transforming the management of human malignancy, particularly breast cancer.
• Understanding the nuances of ADC action, use, and toxicity is crucial for optimizing patient care.